June 20, 2007 – Benda Pharma (BPMA.OB) incrementally increased its ownership of Gendicine, the first gene therapy for cancer, by buying another 2.56% of the stock in the maker of Gendicine, SiBiono. With this latest purchase, Benda now owns 60.13% of the total number of outstanding SiBiono shares. Although Benda produces many traditional Chinese medications, Gendicine is a western style drug for cancer that has been on the market since 2004. Benda, which bought the shares from selling shareholders, did not disclose terms. More details...
